Influence of different haemodialysis modalities on AGE peptide levels: intradialytic versus long-term results.
BACKGROUND
Peptide-linked degradation products of advanced glycation end products (AGE peptides) accumulate in chronic haemodialysis (HD) patients and may contribute to a number of HD-related long-term complications, such as accelerated atherosclerosis.


METHODS
The influence of a single HD session versus long-term HD on serum AGE peptides was determined. The patients were randomized to HD with a low-flux polysulfone (PS; F 6HPS), a high-flux PS (F 60S), a superflux PS (F 500S), or a superflux cellulose triacetate (CTA; Tricea 150G) dialyzer.


RESULTS
During a single HD session, both AGE peptides and reference peptides decreased significantly (AGE peptides: Tricea 150G -37.0 +/- 2.9%; F 6HPS -35.5 +/- 2.4%; F 60S -39.5 +/- 4.7%, and F 500S -43.3 +/- 2.1%, p = 0.005; reference peptides: Tricea 150G -73.2 +/- 8.8%; F 6HPS -73.2 +/- 7.9%; F 60S -72.5 +/- 8.2%, and F 500S -74.1 +/- 7.3%, p = 0.005). After 12 weeks of HD with the superflux CTA, the AGE peptide levels decreased significantly (week 1: 2.7 +/- 1.1 arbitrary units, week 12: 2.5 +/- 1.2 arbitrary units, decrease 7.4%; p = 0.01), whereas the AGE peptide levels remained unchanged after HD with each of the other three modalities. The reference peptide levels did not change after 12 weeks of HD.


CONCLUSIONS
Although AGE peptides can be effectively removed during a single HD session, superflux CTA seems to be the only modality capable of reducing AGE peptides in the long term.
van Tellingen
Anne
A
Department of Nephrology, Medical Centre Alkmaar, Alkmaar, The Netherlands. a.van.tellingen@mca.nl
Schalkwijk
Casper G
CG
Teerlink
Tom
T
Barto
Rob
R
Grooteman
Muriel P C
MP
van der Ploeg
Tjeerd
T
ter Wee
Piet M
PM
Nubé
Menso J
MJ
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D017127:Glycation End Products, Advanced / Q000097:blood*; D006801:Humans; D008297:Male; D008567:Membranes, Artificial; D008875:Middle Aged; D008970:Molecular Weight; D011446:Prospective Studies; D006435:Renal Dialysis
D017127:Glycation End Products, Advanced; D008567:Membranes, Artificial